It also doesn't seem to matter that this district court ruling, if allowed to stand, is likely to leave many patients unnecessarily at high risk for major adverse cardiovascular events and potentially at unnecessary risk for other medical risks, which VASCEPA may be able to address, in which we are in various stages of investigation. The potential benefits of which are less likely to be realized if VASCEPA becomes generic. Unfortunately for patient care, it is not enough to have extraordinary clinical results and FDA drug approval. Health care professionals and patients need product education.